Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare providers. While tirzepatide has been approved by regulatory agencies, its costly nature presents a significant obstacle to many. Ne